Safety of IGIV therapy and infusion-related adverse events

Immunologic Research

Volumn 38, Issue 1-3, 2007, Pages 122-132

  Ballow, Mark ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Adverse events; Immunoglobulin; Intravenous (IGIV); Others uses for IGIV; Primary immune deficiency; Routes of administration; Viral safety

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN A;

ABDOMINAL PAIN; ALOPECIA; ANXIETY; ASEPTIC MENINGITIS; BACKACHE; BIOPSY; BLEEDING DISORDER; BONE MARROW TRANSPLANTATION; CARDIOVASCULAR DISEASE; CHEST TIGHTNESS; CHILL; CHRONIC LUNG DISEASE; CHRONIC LYMPHATIC LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CORONARY ARTERY ANEURYSM; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DONOR SELECTION; DRUG DOSE COMPARISON; DYSPNEA; ERYTHEMA MULTIFORME; FEVER; FLUSHING; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HUMAN; HYPOTENSION; IMMUNE DEFICIENCY; INFUSION RATE; KIDNEY INJURY; KIDNEY TUBULE NECROSIS; LEUKOCYTOCLASTIC VASCULITIS; LUNG EMBOLISM; LUNG FUNCTION TEST; LUNG INJURY; MACULOPAPULAR RASH; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYALGIA; NAUSEA; NEUROMUSCULAR DISEASE; NEUTROPENIA; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETINA VEIN OCCLUSION; SERUM SICKNESS; SHOCK; SIDE EFFECT; STROKE; SUBSTITUTION THERAPY; TACHYCARDIA; THORAX PAIN; TREATMENT INDICATION; TREATMENT OUTCOME; UREMIA; URTICARIA; UVEITIS; VIRUS VIRULENCE; X LINKED AGAMMAGLOBULINEMIA;

HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFUSIONS, INTRAVENOUS;

EID: 35348865528     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12026-007-0003-5     Document Type: Conference Paper

References (34)

1. Brennan VM, Salome-Bentley NJ, Chapel HM. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 2003;133:247-51
2. Burks A, Sampson H, Buckley R. Anaphylactic reactions after gammaglobulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 1986;314:560
3. Cunningham-Rundles C, Zhou Z, Mankarious S, Courter S. Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol 1993;13:272-8
4. de Albuquerque Campos R, Sato MN, da Silva Duarte AJ. IgG Anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy. J Clin Immunol 2000;20:77-82
5. Anonymous. Renal insufficiency and failure associated with immune globulin intravenous therapy - United States, 1985-1998. MMWR Morb Mortal Wkly Rep 1999;48:518-21
6. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994;121:259-62
7. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003;17:241-51
8. Dalakas MC, Clark WM. Strokes, thromboembolic events, and IVIg - Rare incidents blemish an excellent safety record. Neurology 2003;60:1736-7
9. Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000;65:30-4
10. Fisman DN, Smilovitch M. Intravenous immunoglobulin, blood viscosity and myocardial infarction. Can J Cardiol 1997;13:775-7
11. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331:1607-11
12. Bresee JS, Mast EE, Coleman PJ, Baron M, Schonberger L, Alter J, et al. Hepatitis C virus infection associated with administration of intravenous immune globulin. JAMA 1996;276:1563-7
13. Rossi G, Tucci A, Cariani E, Ravaggi A, Rossini A, Radaeli E. Outbreak of hepatitis C virus infection in patients with hematologic disorders treated with intravenous immunoglobulins:different prognosis according to the immune status. Blood 1997;90:1309-14
14. Anonymous. Outbreak of hepatitis C associated with intravenous immunoglobulin administration-United States, October 1993-June 1994. MMWR 1994;43:505-9
15. Ballow M. Intravenous immunoglobulins: clinical experience and viral safety. J Am Pharm Assoc 2002;42:449-59
16. Johnson RT, Gibbs CJ Jr. Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. New Engl J Med 1998;339:1994-2004
17. Brown P. Can Creutzfeldt-Jakob disease be transmitted by transfusion? Curr Opin Hematol 1995;2:472-7
18. Trejo SR, Hotta JA, Lebing W, Stenland C, Storms RE, Lee DC, et al. Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process. Vox Sang 2003;84:176-87
19. Bernatowska E, Madalinski K, Janowicz W, Weremowicz R, Gutkowski P, Wolf HM, et al. Results of a prospective controlled two-dose crossover study with intravenous immunoglobulin and comparison (retrospective) with plasma treatment. Clin Immunol Immunopathol 1987;43:153-62
20. Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1987;1:1075-7
21. Liese JG, Wintergerst U, Tympner KD, Belohradsky BH. High- vs low-dose immunoglobulin therapy in the long-term treatment of x-linked agammaglobulinemia. AJDC 1992;146:335-9
22. Kainulainen L, Varpula M, Liippo K, Svedstrom E, Nikoskelainen J, Ruuskanen O. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol 1999;104:1031-6
23. Quartier P, Debre M, DeBlie J, de Sauverzae R, Sayegh N, Jabado N. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatrics 1999;134:589-96
24. Eibl MM, Wedgwood RJ. Intravenous immunoglobulin: a review. Immunodefic Rev 1989;1:1-42
25. Ashida ER, Saxon A. Home intravenous immunoglobulin by self-administration. J Clin Immunol 1986;6:306-9
26. Schiff R. Transmission of viral infections through intravenous immune globulin. N Engl J Med 1994;331:1649-50
27. Gardulf A, Andersen V, Bjorkander J, Ericson D, Froland SS, Gustafson R, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995;345:365-9
28. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunology 2004;112:1-7
29. Sacher RA, the IVIG Advisory Panel. Intravenous immunoglobulin consensus statement. J Allergy Clin Immunol 2001;108:S139-46
30. Milgrom H. Shortage of intravenous immunoglobulin. Ann Allergy Asthma Immunol 1998;81:97-100
31. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117:S525-53
32. Prete M, Perosa F, Favoino E, Dammacco F. Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease. Clin Exp Med 2005;5:141-60
33. Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rho(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005;106:1532-7
34. Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005;78:275-80